Results Snapshot
Quarterly Analysis Highlights - YoY
Net Sales
YoY Growth in quarter ended Sep 2025 is -28.52% vs -26.93% in Sep 2024
Consolidate Net Profit
YoY Growth in quarter ended Sep 2025 is -45.76% vs 81.27% in Sep 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in quarter ended Sep 2025 is -18.60% vs 82.45% in Sep 2024
Interest
YoY Growth in quarter ended Sep 2025 is 4,300.00% vs -80.00% in Sep 2024
Operating Profit Margin (Excl OI)
YoY Growth in quarter ended Sep 2025 has improved from Sep 2024
Compare Quarterly Results Of Staidson (Beijing) Biopharmaceuticals Co., Ltd. With
Quarterly - Net Sales
QoQ Growth in quarter ended Sep 2025 is -12.02% vs -1.27% in Jun 2025
YoY Growth in quarter ended Sep 2025 is -28.52% vs -26.93% in Sep 2024
Quarterly - Consolidate Net Profit
QoQ Growth in quarter ended Sep 2025 is 65.32% vs -463.64% in Jun 2025
YoY Growth in quarter ended Sep 2025 is -45.76% vs 81.27% in Sep 2024
Quarterly - Operating Profit (PBDIT)
QoQ Growth in quarter ended Sep 2025 is 75.12% vs -1,676.92% in Jun 2025
YoY Growth in quarter ended Sep 2025 is -18.60% vs 82.45% in Sep 2024
Quarterly - Interest
QoQ Growth in quarter ended Sep 2025 is 4,300.00% vs -80.00% in Jun 2025
YoY Growth in quarter ended Sep 2025 is 4,300.00% vs -80.00% in Sep 2024
Quarterly - Operating Profit Margin (Excl OI)
QoQ Growth in quarter ended Sep 2025 has improved from Jun 2025
YoY Growth in quarter ended Sep 2025 has improved from Sep 2024






